GILD PE Ratio & Valuation,Is GILD Overvalued

GILD Relative Valuation

GILD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GILD is overvalued; if below, it's undervalued.

Historical Valuation

Gilead Sciences Inc (GILD) is now in the Fair zone, suggesting that its current forward PE ratio of 14.31 is considered Fairly compared with the five-year average of 11.55. The fair price of Gilead Sciences Inc (GILD) is between 97.77 to 132.98 according to relative valuation methord.

Relative Value

Fair Zone

97.77-132.98

Current Price：120.40

Fair

14.31

9.69

EV/EBITDA

Gilead Sciences Inc. (GILD) has a current EV/EBITDA of 9.69. The 5-year average EV/EBITDA is 8.57. The thresholds are as follows: Strongly Undervalued below 5.97, Undervalued between 5.97 and 7.27, Fairly Valued between 9.87 and 7.27, Overvalued between 9.87 and 11.17, and Strongly Overvalued above 11.17. The current Forward EV/EBITDA of 9.69 falls within the Historic Trend Line -Fairly Valued range.

12.08

EV/EBIT

Gilead Sciences Inc. (GILD) has a current EV/EBIT of 12.08. The 5-year average EV/EBIT is 9.99. The thresholds are as follows: Strongly Undervalued below 6.23, Undervalued between 6.23 and 8.11, Fairly Valued between 11.87 and 8.11, Overvalued between 11.87 and 13.75, and Strongly Overvalued above 13.75. The current Forward EV/EBIT of 12.08 falls within the Overvalued range.

4.99

Gilead Sciences Inc. (GILD) has a current PS of 4.99. The 5-year average PS is 3.69. The thresholds are as follows: Strongly Undervalued below 2.50, Undervalued between 2.50 and 3.10, Fairly Valued between 4.29 and 3.10, Overvalued between 4.29 and 4.89, and Strongly Overvalued above 4.89. The current Forward PS of 4.99 falls within the Strongly Overvalued range.

13.18

P/OCF

Gilead Sciences Inc. (GILD) has a current P/OCF of 13.18. The 5-year average P/OCF is 10.06. The thresholds are as follows: Strongly Undervalued below 6.18, Undervalued between 6.18 and 8.12, Fairly Valued between 12.00 and 8.12, Overvalued between 12.00 and 13.94, and Strongly Overvalued above 13.94. The current Forward P/OCF of 13.18 falls within the Overvalued range.

12.26

P/FCF

Gilead Sciences Inc. (GILD) has a current P/FCF of 12.26. The 5-year average P/FCF is 10.52. The thresholds are as follows: Strongly Undervalued below 7.68, Undervalued between 7.68 and 9.10, Fairly Valued between 11.94 and 9.10, Overvalued between 11.94 and 13.37, and Strongly Overvalued above 13.37. The current Forward P/FCF of 12.26 falls within the Overvalued range.

Gilead Sciences Inc (GILD) has a current Price-to-Book (P/B) ratio of 6.94. Compared to its 3-year average P/B ratio of 5.51 , the current P/B ratio is approximately 26.05% higher. Relative to its 5-year average P/B ratio of 4.98, the current P/B ratio is about 39.55% higher. Gilead Sciences Inc (GILD) has a Forward Free Cash Flow (FCF) yield of approximately 6.13%. Compared to its 3-year average FCF yield of 7.89%, the current FCF yield is approximately -22.26% lower. Relative to its 5-year average FCF yield of 9.16% , the current FCF yield is about -33.03% lower.

6.94

P/B

Median3y

5.51

Median5y

4.98

6.13

FCF Yield

Median3y

7.89

Median5y

9.16

Competitors Valuation Multiple

The average P/S ratio for GILD's competitors is 7.27, providing a benchmark for relative valuation. Gilead Sciences Inc Corp (GILD) exhibits a P/S ratio of 4.99, which is -31.32% above the industry average. Given its robust revenue growth of 2.97%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of GILD increased by 30.35% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 16.61 to 39.28.

The secondary factor is the Revenue Growth, contributed 2.97%to the performance.

Overall, the performance of GILD in the past 1 year is driven by Margin Expansion. Which is more sustainable.

2.97%

7.55B → 7.77B

Revenue Growth

136.48%

16.61 → 39.28

Margin Expansion

-109.10%

-206.01 → 18.75

P/E Change

30.35%

92.37 → 120.40

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Gilead Sciences Inc (GILD) currently overvalued or undervalued?

What is Gilead Sciences Inc (GILD) fair value?

GILD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Gilead Sciences Inc (GILD) is between 97.77 to 132.98 according to relative valuation methord.

How does GILD's valuation metrics compare to the industry average?

What is the current P/B ratio for Gilead Sciences Inc (GILD) as of Dec 15 2025?

As of Dec 15 2025, Gilead Sciences Inc (GILD) has a P/B ratio of 6.94. This indicates that the market values GILD at 6.94 times its book value.

What is the current FCF Yield for Gilead Sciences Inc (GILD) as of Dec 15 2025?

As of Dec 15 2025, Gilead Sciences Inc (GILD) has a FCF Yield of 6.13%. This means that for every dollar of Gilead Sciences Inc’s market capitalization, the company generates 6.13 cents in free cash flow.

What is the current Forward P/E ratio for Gilead Sciences Inc (GILD) as of Dec 15 2025?

As of Dec 15 2025, Gilead Sciences Inc (GILD) has a Forward P/E ratio of 14.31. This means the market is willing to pay $14.31 for every dollar of Gilead Sciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Gilead Sciences Inc (GILD) as of Dec 15 2025?

As of Dec 15 2025, Gilead Sciences Inc (GILD) has a Forward P/S ratio of 4.99. This means the market is valuing GILD at $4.99 for every dollar of expected revenue over the next 12 months.

GILD Valuation